Acus

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acus

Property Description
Active Ingredient Meropenem (Meropenem trihydrate)
Form Powder for solution for injection or infusion
Pharmacological Class Carbapenem Antibiotic
General Purpose Treatment of severe bacterial infections
Origin Synthetic

Acus is the trade name for a highly potent, synthetic medication whose active component is the substance meropenem, classifying it fundamentally as an antibiotic. Meropenem belongs to the carbapenem group, a specialized subcategory within the broader family of beta-lactam antibiotics. The medication is a prescription-only drug typically administered in hospital settings to a diverse patient group, including adults and children. It is formulated as a sterile powder for solution that is reconstituted immediately before use and administered exclusively via the intravenous route. This method ensures rapid delivery to the systemic circulation, a necessity for critical care.

The primary purpose of Meropenem is to serve as a reserve antibiotic strategically utilized against severe and complicated bacterial infections. Its function is profoundly bactericidal, meaning its mechanism actively kills the targeted pathogens. Carbapenem antibiotics are structurally unique because they exhibit stability against destruction by bacterial enzymes known as beta-lactamases, a common defense mechanism developed by resistant bacteria. Meropenem is highly stable to hydrolysis by most clinically important beta-lactamases, which is crucial for its efficacy. This functional advantage makes Acus a reliable choice for empirical treatment of serious conditions like febrile neutropenia and ensures the drug is reserved for critical clinical scenarios caused by multi-drug resistant strains.

What side effects are possible with Acus?

Possible Side Effects and Safety Information

The safety profile of Acus (Meropenem) is defined by official regulatory documents, which classify potential adverse reactions based on the physiological system affected and the frequency of occurrence. The majority of reported effects fall into common or uncommon categories, primarily involving the Gastrointestinal and Hematologic systems.

Frequency-Classified Adverse Reactions

Frequency Classification Associated System-Organ Effects (Examples)
Common (ge 1/100) Diarrhea, nausea, vomiting, headache, rash, pruritus, thrombocythemia, and transient elevations in liver enzymes [EMA SmPC].
Uncommon (ge 1/1,000) Leukopenia, neutropenia, thrombocytopenia, eosinophilia, oral/vaginal candidiasis, and paresthesia.
Rare (ge 1/10,000) Convulsions/seizures and haemolytic anaemia.

Serious Adverse Reactions and Safety Constraints

The official labeling highlights several serious adverse reactions that are relevant across all antibacterial agents and those specific to the carbapenem class. These include potentially life-threatening Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), anaphylaxis, and pseudomembranous colitis [FDA Label]. The medication is formally contraindicated in individuals with a known severe hypersensitivity to any carbapenem or other beta-lactam antibacterial agent.

Population Safety Notes

The regulatory profile specifies increased monitoring for patients with renal impairment or pre-existing Central Nervous System (CNS) disorders, as these groups may face an elevated risk of CNS adverse reactions, including drug-induced seizures. The official labeling notes that Clostridioides difficile-associated diarrhea (CDAD) can manifest during or after the completion of therapy.

Overdose and Emergency Response

Acus Overdose and when to seek help

The official regulatory documents define the overdose profile for Acus (meropenem) by highlighting the potential for serious Central Nervous System (CNS) manifestations.


Overdose Scope and Manifestations

The most significant clinical outcome documented following excessive exposure is the occurrence of seizures or convulsions. This risk is officially compounded in patients with renal impairment, where the drug's reduced clearance can lead to accumulation and heightened toxicity. Dosage adjustments are therefore mandated for patients with compromised renal function to specifically mitigate the risk of overdose. Furthermore, certain regulatory guidance advises that specific formulations must not be used in pediatric patients requiring fractional doses, an explicit measure to prevent unintentional overdose.


Emergency Response and Management

Accidental overdosage requires immediate emergency medical treatment. The mandated management protocol is focused on providing symptomatic and supportive treatment. Since no specific pharmacological antidote is officially known or described in the prescribing information, the clinical strategy involves procedures to remove the drug from the systemic circulation. This is officially accomplished through procedures such as haemodialysis and haemofiltration, both documented as effective methods for clearing excess meropenem from the body.

Therapeutic Uses of Acus

Acus (Meropenem) is applied in clinical settings that involve acute or unstable symptom patterns, which is relevant across domains where short-term symptomatic assistance is appropriate. The main conditions addressed include complicated skin and skin structure infections, complicated intra-abdominal infections, and bacterial meningitis (in pediatric patients).


Key Therapeutic Applications

Acus is used for managing symptoms related to systemic imbalance and symptoms related to heightened physiological activity, which contributes to easing the overall symptom load during episodes of sudden symptom escalation. It is considered relevant for managing symptoms in specific, vulnerable groups, such as pediatric patients (3 months and older) and immunocompromised individuals with febrile neutropenia. The medication is used in settings marked by temporary physiological imbalance, which helps maintain a sense of stability when symptoms are more noticeable.

“Acus is relevant across domains where short-term symptomatic assistance is appropriate, including conditions where symptoms are linked to organ-specific functional stress.”

Addressing Complex Symptom Patterns

This medication is relevant in contexts marked by increased discomfort or tension, such as those in intra-abdominal infections and extensive complicated skin and soft tissue infections. Its use assists with easing the overall symptom burden, and it is generally applied across conditions presenting with acute episodes where symptoms may intensify temporarily.

Quick Fact: Relief for Systemic Strain
Acus supports the patient by managing symptoms related to systemic imbalance and heightened physiological activity, which helps ease the overall symptom load during episodes of sudden symptom escalation.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Acus (Meropenem) — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label) Populations for whom use is contraindicated
Adults and adolescents ge 12 years. Patients with known hypersensitivity to Meropenem.
Children aged 3 months to 11 years for approved indications. Patients with a history of severe hypersensitivity (e.g., anaphylaxis) to any other beta-lactam antibacterial agents (penicillins, cephalosporins).

Age-Related and Conditional Eligibility

Age-Related Eligibility Rules Condition-Specific Eligibility Rules
Use is not recommended in infants under 3 months of age due to unestablished safety and efficacy. Renal Impairment requires mandatory dose reduction in adults and adolescents with a creatinine clearance le 50 mL/min.
Older adults with normal renal function are generally eligible; adjustments are based on renal status. Use requires caution in patients with a history of Central Nervous System disorders (e.g., history of seizures).

Pregnancy and Lactation Eligibility Status

The use of Acus is generally not recommended during pregnancy or breastfeeding. This is a conditional restriction applied because safety has not been established in human pregnancy, and the medicine is known to be excreted in small amounts into human milk. Use during these periods is only permitted if the potential benefit is determined to outweigh the risk, as defined in official regulatory documents.

Connection to the overall eligibility profile

Official regulatory documents establish that eligibility is strictly governed by absolute contraindications based on hypersensitivity history. Beyond this exclusion, the profile details conditional use determined by minimum age thresholds (ge 3 months), organ function (renal status), and physiological states (pregnancy/lactation), confining the use to populations where its administration is officially sanctioned or carefully managed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Acus (Meropenem) is defined by its effects on the concentrations and clearance of specific co-administered medicines, as documented by regulatory authorities.

Documented Interaction Patterns

The most significant documented interaction involves Valproic Acid and its derivatives (Divalproex Sodium, Valpromide). Co-administration is not recommended by regulatory bodies because Acus causes a rapid and substantial reduction in valproic acid serum concentrations. This effect is attributed to interference with valproic acid metabolism, leading to a risk of sub-therapeutic levels. This risk is officially noted as being higher for patients with pre-existing Central Nervous System (CNS) disorders or compromised renal function.

Another specific interaction concerns Probenecid. Co-administration is likewise not recommended because Probenecid competes with meropenem for active tubular secretion in the kidney, which inhibits meropenem's excretion. This process is documented to result in an increase in meropenem plasma concentrations.

Meropenem is also noted to be associated with an increase in the effect of oral anticoagulants such as Warfarin, which may require monitoring of the International Normalized Ratio (INR). Regulatory documents confirm that Acus exhibits minimal interaction with the cytochrome P450 enzyme system. No specific interactions with food, alcohol, or herbal products are explicitly documented in the official labeling.

Mechanism of Action

How Acus Works: Mechanism of Action


Irreversible Disruption of Bacterial Cell Wall Assembly

The active substance, meropenem, initiates its effect by covalently and irreversibly binding to Penicillin-Binding Proteins (PBPs)—bacterial enzymes crucial for cross-linking the structural polymer peptidoglycan. By permanently inhibiting this final step in the cell wall synthesis pathway, the drug functionally removes the structural integrity of the microbial architecture.


Causal Cascade of Osmotic Lysis

The loss of a rigid, intact cell wall prevents the bacterium from counteracting its own high internal pressure, which immediately triggers a mechanistic cascade resulting in rapid cell swelling and osmotic lysis (rupture). This direct, destructive action ensures a bactericidal effect, leading to the swift physiological consequence of microbial death.


Stability Against Key Resistance Pathways

Meropenem's mechanism incorporates structural defenses, granting it functional stability against hydrolysis by the majority of bacterial serine beta-lactamases (e.g., ESBLs). This stability allows the drug to maintain its binding affinity for PBPs and sustain its inhibitory action.

Dosage and Administration Information

Acus (meropenem) is a prescription-only medication administered exclusively via the intravenous route. Its high-level usage is defined by precise protocols covering dosing, frequency, and preparation. The medication is supplied as a sterile powder that requires reconstitution using aseptic technique with specific sterile diluents prior to administration.

The standard administration schedule is fixed at an interval of every eight hours (three times daily) for adult patients exhibiting normal renal function. The unit dose typically ranges from 500 mg to 2 grams, with the specific amount selected based on the infection severity and site, reaching a maximum of 6 grams daily in divided doses. Administration must occur over a set time: either as an Intravenous Infusion over 15 to 30 minutes, or as an Intravenous Bolus Injection over three to five minutes, restricted to doses up to 1 gram.

For certain populations, the standard schedule requires adjustment. Patients with impaired renal function must have the unit dose reduced and/or the interval extended when creatinine clearance is le 50 mL/min. Dosing for pediatric patients under 50 kg is determined on a weight-based (mg/kg) calculation. The total treatment duration is typically between 7 and 21 days. Furthermore, the reconstituted solution must not be mixed with other medicinal products.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy and Joint Health

Research on the compound primarily focuses on individuals experiencing mild to moderate joint discomfort, particularly related to osteoarthritis.

  • Studies evaluated whether it impacts joint health and function, with several randomized controlled trials (RCTs) reporting mixed results regarding functional improvement.
  • Research investigated its potential relationship with pain and stiffness relief in individuals with mild to moderate osteoarthritis, suggesting potential benefits in specific patient subgroups.

Research Focus and Actions

The way the compound may act is still under investigation.

Specific research pathways have been investigated, such as exploring:

  1. Cartilage Cell Activity: In some non-clinical studies, an association was found with biological activity in cartilage cells.
  2. Inflammation: Other studies have focused on its potential relationship with inflammation.

Combinational and Long-Term Research

The compound is frequently studied in combination with other ingredients, such as chondroitin sulfate.

  • Combination Studies: The combination has been explored in relation to mobility and perceived long-term quality of life, with some meta-analyses suggesting small to moderate effects on pain and function when used together.
  • Duration of Study: Study protocols have typically involved a duration of at least 3 months to assess changes in symptoms.

Safety and Side Effects

The compound's tolerability has been a standard focus in clinical trials.

  • Tolerability: Adverse events reported in trials were often mild, and typically involved temporary gastrointestinal upset (e.g., nausea, mild diarrhea).
  • Contraindications: The compound has been researched as an option for individuals seeking non-prescription management of joint discomfort. Individuals with known shellfish allergies should be aware that the compound is often derived from marine sources. Evidence remains limited regarding its use during pregnancy or lactation.

Key Studies & References

  1. NICE Guideline NG212: Osteoarthritis: care and management in adults

Frequently Asked Questions (FAQ)

Common questions about Acus (FAQ)

Q: How quickly does Acus start to work for pain relief?

A: Official regulatory information clarifies that Acus is a carbapenem antibiotic intended to fight severe bacterial infections. Official documents clarify it is not intended for use as a pain-relieving medication (analgesic).

Q: Will I feel different right after taking the first dose of Acus?

A: Since Acus is administered intravenously for serious infections, its primary action is against the bacteria. While some patients commonly report immediate side effects such as a headache, nausea, or vomiting, a major immediate change in overall well-being is not commonly documented.

Q: Can Acus cause stomach upset, and what helps with that?

A: Gastrointestinal issues, including diarrhea, nausea, and vomiting, are commonly reported side effects according to the official product information. It is important to inform the healthcare professionals managing your treatment if these symptoms are severe or persistent.

Q: Is it normal to feel a bit tired when starting Acus?

A: Official reports indicate that fatigue, sometimes referred to as asthenia, has been reported as an uncommon or rare side effect in clinical trials. If unusual fatigue is experienced, inform the healthcare team.

Q: Is there a known interaction between Acus and caffeine or coffee?

A: Official regulatory documents specifically state that no interactions with food, alcohol, or herbal products have been documented in the drug labeling. The official documentation does not list specific interactions with common beverages like coffee or caffeine.

Q: Does Acus interact with common over-the-counter pain relievers?

A: The official product information lists specific, significant interactions with prescription medications like Valproic Acid and Probenecid. It does not list known interactions with common over-the-counter pain relievers such as ibuprofen or acetaminophen.

Q: How long after stopping Acus will it be completely out of my system?

A: Meropenem, the active ingredient in Acus, is mainly processed and cleared by the kidneys. For adults with normal kidney function, the drug has a short half-life of approximately one hour. This means that a significant portion of the medication is typically eliminated from the body within a few hours.

Q: Is Acus safe to take with common heartburn medications like antacids?

A: Official regulatory documents do not list specific interactions between intravenous Acus and common heartburn medications or antacids. Your healthcare provider will review all medications being used.

Q: Do you need to get blood tests while taking Acus?

A: Because Acus can cause reported changes in liver enzymes and blood cell counts, monitoring of liver function and blood counts is often part of the treatment plan. This ensures the medication is being managed according to standard medical practice.

Q: Are there any serious, but rare, side effects of Acus I should know about?

A: Official warnings note the potential for several serious, but rare, reactions. These include severe allergic reactions (anaphylaxis), convulsions (seizures), severe skin reactions, and Clostridioides difficile-associated diarrhea (CDAD).

Q: Does Acus have a ceiling dose beyond which increasing it offers no extra benefit?

A: Official dosing information specifies a maximum recommended daily dose, such as 6 grams for adults. Doses are calculated and adjusted by healthcare professionals based on factors like the type of infection and the patient’s kidney function.

Q: Are the side effects of Acus worse for older patients?

A: Official information indicates that older adults are more likely to have age-related decline in kidney function. For this reason, dose adjustment is necessary if kidney function is impaired, but no specific increase in other non-kidney-related side effects is routinely noted for older adults with normal kidney function.

Q: Is Acus considered safe for use in teenagers?

A: Acus is labeled for use in adolescents aged 12 years and older. Dosing for teenagers is determined by their weight or by using the standard adult dose, depending on their size, as outlined in the official prescribing information.

Q: What should I do if I accidentally miss a dose of Acus?

A: If a dose is missed, patients are advised to contact their healthcare provider right away for specific guidance. Patients should be guided by their healthcare provider; extra medicine should not be administered without instruction.

Q: If I stop taking Acus suddenly, will I have withdrawal symptoms?

A: Acus is a short-course antibiotic used to treat acute infections. Based on its official mechanism of action and regulatory reports, there are no documented withdrawal symptoms associated with the sudden cessation of this therapy.

Q: Do you need a special diet while on Acus?

A: According to the official product information, there are no specific dietary modifications or restrictions documented to be necessary while receiving Acus.

Q: Why do doctors often prescribe a starting dose and then adjust it for Acus?

A: The dosage for Acus is not fixed. It is precisely calculated based on the type and severity of the bacterial infection being treated, as well as the patient’s individual kidney function. This individualized approach ensures the correct concentration of the antibiotic is delivered.

Q: Can Acus affect your sleep schedule?

A: The drug’s official safety profile notes rare side effects affecting the Central Nervous System (CNS), such as seizures or confusion. There have also been reports of sleepiness or difficulty sleeping.

Q: What published research supports the use of Acus for its main indication?

A: The efficacy and approval of Acus are supported by multi-center clinical trials that compare it to other treatments for its approved indications, such as complicated infections like bacterial meningitis.

Q: Does Acus come in different strengths, and how do I know which one is being discussed?

A: Acus (Meropenem) is typically supplied in sterile vials containing either 500 mg or 1 gram of the powder for reconstitution. The dose prescribed is determined by the healthcare provider to match the specific needs of the patient and the infection.

Q: Why does Acus have to be taken with food?

A: Acus is not taken orally (by mouth) and is not affected by food consumption. It is administered exclusively through an intravenous (IV) injection or infusion, ensuring it bypasses the digestive system entirely.

Q: What happens if I take Acus on an empty stomach?

A: Since Acus is administered exclusively through an intravenous (IV) line, its use is not dependent on the patient's stomach being full or empty.

Q: Is Acus safe for women who are trying to conceive?

A: Acus is not generally recommended for use during pregnancy because its safety has not been fully established. Patients who are planning to become pregnant are advised to seek guidance from their healthcare provider regarding their treatment needs.

Q: Can Acus cause changes in appetite or weight?

A: In some post-marketing and clinical trial reports, rare side effects such as loss of appetite and unusual changes in weight have been noted in the official product information.

Q: What's the difference between the immediate-release and extended-release forms of Acus?

A: Acus (Meropenem) is typically formulated as a sterile powder for intravenous use (injection or infusion). Regulatory labeling for the standard product does not list immediate-release or extended-release oral tablet forms.

Q: How long do most people stay on Acus for chronic conditions?

A: Acus is a powerful antibiotic used for acute, severe bacterial infections. The documented duration of treatment is typically short, ranging between 7 and 21 days, and it is not generally intended for long-term or chronic use.

Q: Is Acus known to cause any changes in mood or anxiety levels?

A: Side effects affecting the central nervous system, such as agitation, confusion, and hostility, have been noted as rare adverse events in regulatory documents. A direct effect on general mood or anxiety is not specifically reported.

Q: If I have mild liver problems, can I still take Acus?

A: Official product information suggests that a dose adjustment is typically not required solely for patients with liver impairment, but monitoring of liver function is advised during treatment.

Q: Why is Acus not suitable for very young children?

A: The drug is not recommended for infants younger than three months of age because regulatory studies have not fully established the safety and effectiveness for this age group.

How should Acus be stored and disposed of?

How to Store and Dispose of Acus?

The storage of Acus (meropenem powder) is regulated by strict, official requirements to maintain its stability and effectiveness.

Storage Conditions and Stability

  • The unreconstituted powder must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container and protected from moisture.
  • The prepared intravenous solution must not be frozen. The stability of the solution is highly time-sensitive; for instance, when mixed with 0.9% saline, it is stable for up to 15 hours under refrigeration (2 C to 8 C).

Child Safety and Disposal

  • All medicine must be stored out of the sight and reach of children.
  • Disposal of any unused or expired product must be carried out according to local requirements and must not be poured into wastewater or discarded with ordinary household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acus found in:

A-Z Index: